Company intelligence / Profile preview
Evox Therapeutics
- Ownership
- Private
- Development stage
- Preclinical
Overview
Evox has demonstrated robust preclinical proof-of-concept data showing efficient CNS delivery and functional activity of exosome-loaded CRISPR editors, mRNAs, proteins, and RNAi agents. In vivo rodent studies show high levels of gene recombination or silencing after direct CNS injection. The company’s lead programs are advancing toward first-in-human trials targeting severe rare neurological disorders.
- Therapeutic areas
- Metabolic DisordersRare DiseasesNeurology
- Modalities
- Exosome-based therapeutics (engineered extracellular vesicles)Genome editing (CRISPR/Cas-based)mRNA deliveryProtein replacement therapyRNAi/siRNA/shRNA delivery
- Industry
- Biotech
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Evox Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evox Therapeutics.